5-HT3 antagonists

Sense Relief Receives Grant From UCSF-Stanford Pediatric Device Consortium for Further Development and Study of the Treatment for Pregnancy Related Nausea and Vomiting

Retrieved on: 
Monday, June 28, 2021
Vomiting, Digestive diseases, Symptoms and signs, Clinical medicine, Nausea, Antiemetics, Ketones, 5-HT3 antagonists, Oncology

SAN FRANCISCO, June 28, 2021 /PRNewswire/ --Sense Relief, Inc. received an innovation grant from the UCSF-Stanford Pediatric Device Consortium for the continued technical development and further clinical study of Sense Relief, an antiemetic digital therapeutic.

Key Points: 
  • SAN FRANCISCO, June 28, 2021 /PRNewswire/ --Sense Relief, Inc. received an innovation grant from the UCSF-Stanford Pediatric Device Consortium for the continued technical development and further clinical study of Sense Relief, an antiemetic digital therapeutic.
  • The study will help determine the efficacy of this novel health wearable treatment method, understand usage patterns, and classify the causes of nausea, such as medication-induced nausea, stress-related nausea, and vestibularneuritis.
  • The technical development of Sense Relief will integrate CardinalKit to support an ongoing consumer study of thousands of Sense Relief users.
  • The Sense Relief app is available for download to the Apple Watch to help ease symptoms of nausea.

Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti®

Retrieved on: 
Wednesday, June 2, 2021
Medical specialties, Gastroenterology, Digestive diseases, Antiemetics, Chloroarenes, Prolactin releasers, 5-HT3 antagonists, Gastroparesis, Metoclopramide, Food and Drug Administration, United States patent law

Gimoti is Evokes nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis.

Key Points: 
  • Gimoti is Evokes nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis.
  • The U.S. Food and Drug Administration (FDA) approved the New Drug Application for Gimoti in June 2020.
  • We are pleased to announce the issuance of this new U.S. patent which further validates that Gimoti is innovative and novel.
  • The issuance of this patent strengthens the intellectual property protection for Gimoti and supports our commercial efforts to make Gimoti the treatment of choice in the gastroparesis market.

Global Irritable Bowel Syndrome with Constipation Drugs Market (2020 to 2028) - Players Include Abbott Laboratories, Astellas Pharma and Bayer Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 25, 2021
Health, Pharmaceutical, Digestive diseases, Clinical medicine, Medical specialties, Irritable bowel syndrome, Constipation, Abdominal pain, 5-HT3 antagonists, Alosetron, Renzapride

The "Irritable Bowel Syndrome with Constipation Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2020 to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Irritable Bowel Syndrome with Constipation Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2020 to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Irritable bowel syndrome (IBS) is defined as persistent abdominal discomfort and pain occurring with changed bowel habits.
  • The IBS market is observed to be underpenetrated and hence is deemed attractive for pharmaceutical manufacturers in the GI drugs market.
  • This report on global irritable bowel syndrome with constipation (IBS-C) drugs evaluates the current market scenario and predicts future market trends for the commercialized and pipeline drugs for IBS-C treatment for the period from 2018 to 2028.

Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US

Retrieved on: 
Thursday, August 20, 2020
Drugs, Antiemetics, Clinical medicine, Health, 5-HT3 antagonists, RTT, Netupitant/palonosetron, Oncology, Netupitant, Palonosetron, Chemotherapy, Cyclophosphamide

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: At Helsinn, we are unwavering in our pursuit to help patients and clinicians in cancer care.

Key Points: 
  • Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: At Helsinn, we are unwavering in our pursuit to help patients and clinicians in cancer care.
  • Paul Rittman, CEO, Helsinn Therapeutics (U.S.), Inc, said: We are very pleased to launch the new IV solution of AKYNZEO, which provides customers with operational advantages for storage, handling, preparation, and administration.
  • AKYNZEO (fosnetupitant 235mg/palonosetron 0.25) for injection was approved in April 2018 and AKYNZEO injection was approved in May 2020 in the United States.
  • AKYNZEO for injection and AKYNZEO injection have not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.

Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS) and Provides Progress Update on COVID-19 antibody tests

Retrieved on: 
Wednesday, August 12, 2020
Clinical medicine, Medical specialties, Medicine, Abdominal pain, Irritable bowel syndrome, RTT, Gastroenterology, 5-HT3 antagonists, Diagnostic gastroenterology, ALCAT test, Alosetron

Since the InFoods IBS product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects.

Key Points: 
  • Since the InFoods IBS product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects.
  • Further the company expects the clinical trial sites will be active users of the product upon clearance by the FDA.
  • Biomerica has several additional U.S. and international patent applications in prosecution that cover other claims pertaining to the InFoods IBS product.
  • This patented, diagnostic-guided therapy is designed to allow for a patient specific, guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes.

Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States

Retrieved on: 
Tuesday, June 2, 2020
Drugs, Antiemetics, Health, Medicine, 5-HT3 antagonists, RTT, Membrane biology, Phospholipids, Netupitant/palonosetron, Palonosetron, Netupitant, Lecithin

AKYNZEO injection does not contain polysorbate 80 or allergenic excipients such as soy or egg lecithin.

Key Points: 
  • AKYNZEO injection does not contain polysorbate 80 or allergenic excipients such as soy or egg lecithin.
  • Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: We are pleased to announce FDAs approval of the liquid formulation of AKYNZEO.
  • AKYNZEO (fosnetupitant 235mg/palonosetron 0.25) for injection was approved in April 2018 and AKYNZEO injection was approved in May 2020 in the United States.
  • AKYNZEO for injection and AKYNZEO injection have not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.

Knight Therapeutics Announces Approval of IBSRELA™ in Canada

Retrieved on: 
Friday, April 17, 2020
Digestive diseases, RTT, Clinical medicine, Medicine, Knight Therapeutics, Irritable bowel syndrome, Constipation, 5-HT3 antagonists

MONTREAL, April 17, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (Knight) a pan-American (ex-USA) specialty pharmaceutical company, announced that Health Canada has approved IBSRELA (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

Key Points: 
  • MONTREAL, April 17, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (Knight) a pan-American (ex-USA) specialty pharmaceutical company, announced that Health Canada has approved IBSRELA (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
  • Knight and Ardelyx, Inc.(NASDAQ: ARDX) signed an agreement in March 2018 granting Knight the exclusive right to distribute IBSRELA in Canada for IBS-C and hyperphosphatemia.
  • We are excited to receive approval for this promising new treatment option for patients suffering from IBS-C, said Jonathan Ross Goodman, chief executive officer of Knight.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America.

Chemotherapy Induced Nausea & Vomiting - 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 20, 2020
Health, Pharmaceutical, Medicine, Clinical medicine, Health, Oncology, Antineoplastic drugs, Antiemetics, 5-HT3 antagonists, Chemotherapy-induced nausea and vomiting, Chemotherapy, Nausea, Vomiting, Cancer and nausea

The latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2020, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape.

Key Points: 
  • The latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2020, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape.
  • Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs.
  • The Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects.

Reliefband® Wearable Devices for the Prevention and Treatment of Nausea Symptoms Receive FDA Approval for Expanded Uses

Retrieved on: 
Monday, January 6, 2020
Medicine, Clinical medicine, Medical specialties, RTT, Antiemetics, 5-HT3 antagonists, Vomiting, Nausea, Morning sickness, Migraine, Motion Sickness, Indication

The expanded use indications were approved for Reliefband products including the Classic and Premier models, as well as the new Reliefband Travel and Reliefband Sport models unveiled today at CES 2020.

Key Points: 
  • The expanded use indications were approved for Reliefband products including the Classic and Premier models, as well as the new Reliefband Travel and Reliefband Sport models unveiled today at CES 2020.
  • The expanded indications join Reliefband's existing FDA-approved indications for symptoms associated with motion sickness, chemotherapy, morning sickness and nausea from postoperative surgery (as an adjunct to antiemetics).
  • Reliefband is an over-the-counter transdermal neuromodulation device that is applied to the underside of the wrist.
  • "There are more than 38 million people in the U.S. who suffer migraines and the most common associated symptoms are nausea and vomiting.

Global Irritable Bowel Syndrome (IBS) Market to 2026 - Background, Treatment, Epidemiology, Marketed Drugs, Pipeline Drugs, Regulatory Events, Licensing And Asset Acquisition Deals, Patents

Retrieved on: 
Wednesday, June 19, 2019
Health, Life sciences, Medicine, Abdominal pain, Irritable bowel syndrome, RTT, Novartis, GlaxoSmithKline, Allergan, 5-HT3 antagonists, Imidazoles

DUBLIN, June 19, 2019 /PRNewswire/ -- The "Market Spotlight: Irritable Bowel Syndrome (IBS)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 19, 2019 /PRNewswire/ -- The "Market Spotlight: Irritable Bowel Syndrome (IBS)" report has been added to ResearchAndMarkets.com's offering.
  • Half of the industry-sponsored drugs in active clinical development for IBS are in Phase II, with only one drug in the NDA/BLA phase.
  • There have been 21 licensing and asset acquisition deals involving IBS drugs during 2013-18.
  • Allergan leads industry sponsors with the highest number of clinical trials for IBS, followed by GlaxoSmithKline and Novartis